Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
Race Oncology receives positive results from AML trial of Bisantrene
MP3•Episodio en casa
Manage episode 431551800 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episodios
MP3•Episodio en casa
Manage episode 431551800 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episodios
すべてのエピソード
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.